Aquestive Therapeutics

Aquestive Therapeutics Overview

Status Public
Employees 232
Stock Symbol AQST
Stock Symbol
Investments 3
Share Price $5.31 (As of Monday Closing)

Aquestive Therapeutics General Information


Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.

Contact Information

Formerly Known As
MonoSol Rx
Ownership Status
Publicly Held
Financing Status
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aquestive Therapeutics Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.31 $4.87 $1.41 - $10.00 $178M 33.6M 943K -$2.53

Aquestive Therapeutics Financials Summary

In Thousands,
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 84,557 231,462 139,958
Revenue 48,731 52,609 67,430 66,918
EBITDA (55,342) (54,659) (50,981) 2,565
Net Income (68,050) (66,246) (61,376) (8,943)
Total Assets 64,487 78,479 86,851 43,116
Total Debt 64,955 60,338 47,203 45,507
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aquestive Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aquestive Therapeutics‘s full profile, request access.

Request a free trial

Aquestive Therapeutics Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Cure Pharmaceutical Angel-Backed Oxnard, CA 00 0000 00000 0000
00000000 Corporation Basel, Switzerland 000000 000000000000
00000 000000000000 Formerly VC-backed Bridgewater, NJ 0000 00000 000000&0
0. 00000000-00 000 Corporation Basel, Switzerland 00000 00000 00000000000
0000000000 0000000 Corporation Ingelheim am Rhein, Germany 00000

Aquestive Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Keith Kendall Chief Executive Officer & Board Member
John Maxwell Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Daniel Barber Chief Operating Officer, Operations & Senior Vice President
Mark Schobel Chief Innovation & Technology Officer
Ken Marshall Executive

2 Former Executives

Aquestive Therapeutics Board Members (4)

To view Aquestive Therapeutics‘s full board member team, request access »
Name Representing Role Since
00000 00000000 Self Board Member 000 0000
00000 0000000 Aquestive Therapeutics Chief Executive Officer & Board Member 000 0000
00000 000000 Self Board Member 000 0000

1 Former Board Member

Aquestive Therapeutics Investments (3)

To view Aquestive Therapeutics‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 00000000 29-May-2007 0000000000 00000 Other Commercial Products 000 00000
00000000 (0000000 29-May-2007 0000000000 Other Containers and Packaging
RespondTV 26-Jul-2000 Later Stage VC 000.00 Social Content

Ready to get started?

Request a free trial

Aquestive Therapeutics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 26-Jul-2000 00000 00000 00 000.00 Completed
  • 8 buyers